{"nctId":"NCT02932267","briefTitle":"Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne","startDateStruct":{"date":"2017-02-02","type":"ACTUAL"},"conditions":["Acne Vulgaris"],"count":50,"armGroups":[{"label":"Adapalene / BPO gel","type":"EXPERIMENTAL","interventionNames":["Drug: Adapalene 0.3% / BPO 2.5% gel"]}],"interventions":[{"name":"Adapalene 0.3% / BPO 2.5% gel","otherNames":["Epiduo Forte / Tactupump gel"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject with clinical diagnosis of moderate to severe facial acne vulgaris, defined by:\n\n  1. Investigator's Global Assessment (IGA) score of 3 (Moderate) OR 4 (Severe ); and\n  2. A minimum of 25-100 inflammatory lesions (papules and pustules); and\n  3. A minimum of 30-150 non-inflammatory lesions (open and closed comedones) in total (excluding the nose); and\n  4. No more than two acne nodules (â‰¥ 1 cm),\n* Subject with skin phototype IV to VI on Fitzpatrick skin phototype scale,\n* Subjects from one of the 3 ethnic/race backgrounds: Asian, Latin American and Black/African-American,\n\nExclusion Criteria:\n\n* Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, acne requiring systemic treatment,\n* Subject with history of lupus, atopic dermatitis, perioral dermatitis, dermatomyositis, rosacea\n* Female subject who is pregnant, lactating or planning a pregnancy during the trial,\n* Subjects having received at least one of the following topical treatments on the treated area: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, dapsone, hydroxyacids, Zinc containing treatments, antiseptics, other anti-inflammatory products or other acne treatments (2 weeks); Retinoids (4 weeks); Cosmetic/aesthetic procedures on the face (1 week); Wax epilation (2 weeks); Photodynamic therapy (6 weeks); Laser therapy, microdermabrasion, deep chemical peel, plastic surgery for acne (3 months).\n* Subjects having received at least one of the following systemic treatments: Corticosteroids, tetracyclines, other antibiotics (except penicillin) (1 month); Oral retinoids/isotretinoin/ anti-androgens / Cyproterone acetate / Chlormadinone acetate (6 months); Spironolactone/ Drospirenone (3 months); Immunomodulators (3 months) and Oral contraceptives/ oral dapsone for acne(1 month).","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire","description":"% of subjects satisfied to very satisfied with study treatment at week 12","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Headache","Pyrexia","Post inflammatory pigmentation change","Pruritus"]}}}